Cancéropôle CLARA, Lyon, France.
MAbs. 2012 Jul-Aug;4(4):434-44. doi: 10.4161/mabs.20869. Epub 2012 Jul 1.
The Innovative Approaches in Anti-Cancer Monoclonal Antibodies meeting, held on March 20, 2012 in Lyon, was organized by Cancéropôle Lyon Auvergne-Rhône-Alps in partnership with the French competitiveness cluster Lyonbiopôle. CLARA is one of the seven cancer research clusters within France in charge of facilitating Translational Oncology Research by taking into account the objectives of the French National Cancer Plans I and II and, in coordination with the French National Cancer Institute and local authorities (mainly Grand Lyon, Rhône County and Rhône-Alpes Region), to perform economic development of research findings. The contribution of lectures by outstanding speakers as described in this report, the organization of two-round tables: "Antibody treatment in cancer: Unmet needs in solid tumors and hematological malignancies," and "From chimeric to more than human antibodies," together with face-to-face meetings, was shared by over 230 participants. The lectures provided an overview of the commercial pipeline of monoclonal antibody (mAb) therapeutics for cancer; discussion of the distinction between biosimilar, biobetter and next generation therapeutic antibodies for cancer; updates on obinutuzumab and the use of mAbs in lymphoma; and discussion of antibody-drug conjugates.
2012 年 3 月 20 日在里昂举行的抗癌单克隆抗体创新方法会议由里昂奥弗涅-罗讷-阿尔卑斯癌症集群与法国竞争力集群 Lyonbiopôle 合作组织。CLARA 是法国七个癌症研究集群之一，负责通过考虑法国国家癌症计划 I 和 II 的目标并与法国国家癌症研究所和地方当局（主要是大里昂、罗讷县和罗纳-阿尔卑斯地区）协调，促进转化肿瘤学研究，从而对研究成果进行经济开发。本报告中描述的杰出演讲者的讲座、“抗体治疗癌症：实体瘤和血液恶性肿瘤的未满足需求”和“从嵌合到超越人类的抗体”两轮圆桌会议的组织以及面对面会议的组织，由 230 多名参与者共同参与。这些讲座概述了用于癌症的单克隆抗体 (mAb) 治疗药物的商业管线；讨论了癌症的生物相似、生物改良和下一代治疗性抗体之间的区别；更新了奥滨尤妥珠单抗以及 mAb 在淋巴瘤中的应用；并讨论了抗体药物偶联物。
